PortalPublikationenThe ZOTECT study

The ZOTECT study

Standard

The ZOTECT study : Effect of zoledronic acid on bone metabolism in patients with bone metastases from prostate or breast cancer. / Hadji, Peyman; Ziller, May; Maurer, Tobias; Autenrieth, Michael; Muth, Mathias; Ruebel, Amelie; May, Christoph; Birkholz, Katrin; Diebel, Erhardt; Gleissner, Jochen; Rothe, Peter; Gschwend, Juergen E.

in: J BONE ONCOL, Jahrgang 1, Nr. 3, 12.2012, S. 88-94.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung

Harvard

Hadji, P, Ziller, M, Maurer, T, Autenrieth, M, Muth, M, Ruebel, A, May, C, Birkholz, K, Diebel, E, Gleissner, J, Rothe, P & Gschwend, JE 2012, 'The ZOTECT study: Effect of zoledronic acid on bone metabolism in patients with bone metastases from prostate or breast cancer', J BONE ONCOL, Jg. 1, Nr. 3, S. 88-94. https://doi.org/10.1016/j.jbo.2012.07.002

APA

Hadji, P., Ziller, M., Maurer, T., Autenrieth, M., Muth, M., Ruebel, A., May, C., Birkholz, K., Diebel, E., Gleissner, J., Rothe, P., & Gschwend, J. E. (2012). The ZOTECT study: Effect of zoledronic acid on bone metabolism in patients with bone metastases from prostate or breast cancer. J BONE ONCOL, 1(3), 88-94. https://doi.org/10.1016/j.jbo.2012.07.002

Vancouver

Hadji P, Ziller M, Maurer T, Autenrieth M, Muth M, Ruebel A et al. The ZOTECT study: Effect of zoledronic acid on bone metabolism in patients with bone metastases from prostate or breast cancer. J BONE ONCOL. 2012 Dez;1(3):88-94. https://doi.org/10.1016/j.jbo.2012.07.002

Bibtex

@article{cc1b79efbc9f4fbf8cb8ee2655d9a2a3,
title = "The ZOTECT study: Effect of zoledronic acid on bone metabolism in patients with bone metastases from prostate or breast cancer",
abstract = "PURPOSE: The ZOTECT study assesses the effect of zoledronic acid (ZOL) on bone-marker levels and potential correlations with disease outcomes in bisphosphonate-naive patients.METHODS: This prospective, single-arm, open-label study in bisphosphonate-naive (≥6 months) patients with bone metastases from prostate cancer (PC; n=301) or breast cancer (BC; n=99) enrolled at 98 German sites (May 2006 to July 2008) investigated the effect of ZOL (4 mg intravenously every 4 weeks×4 months, with a final follow-up at 12 months) on bone-marker levels. Secondary assessments: skeletal-related event (SRE) rate, pain, quality of life (QoL), and prostate-specific antigen levels. Endpoints were assessed using summary statistics by visit/tumor type and Kaplan-Meier analyses.RESULTS: ZOL treatment significantly decreased bone-marker levels (amino-terminal propeptide of type I collagen [P1NP], C-terminal cross-linking telopeptide of type I collagen [CTX]; P<0.0001), and this decrease was maintained through the final 1-year follow-up visit. Baseline P1NP and CTX levels correlated with extent of bone disease (P<0.0001, each) and on-treatment decreases in marker levels. Skeletal disease burden and bone-marker levels were similar between PC and BC patients, and ZOL did not significantly influence osteoprotegerin/receptor activator of nuclear factor-κB ligand levels. Only 13 SREs occurred in 11 patients, supporting the known ZOL-mediated reduction in SREs. On-treatment bone-marker level changes did not correlate with SRE rate, pain scores, or QoL. Generally, ZOL was well tolerated and adverse events were consistent with its known safety profile.CONCLUSIONS: This study confirms that ZOL therapy significantly reduces bone turnover (measured as P1NP and CTX levels) in patients with bone metastases from PC or BC.",
keywords = "Journal Article",
author = "Peyman Hadji and May Ziller and Tobias Maurer and Michael Autenrieth and Mathias Muth and Amelie Ruebel and Christoph May and Katrin Birkholz and Erhardt Diebel and Jochen Gleissner and Peter Rothe and Gschwend, {Juergen E}",
year = "2012",
month = dec,
doi = "10.1016/j.jbo.2012.07.002",
language = "English",
volume = "1",
pages = "88--94",
journal = "J BONE ONCOL",
issn = "2212-1374",
publisher = "Elsevier GmbH",
number = "3",

}

RIS

TY - JOUR

T1 - The ZOTECT study

T2 - Effect of zoledronic acid on bone metabolism in patients with bone metastases from prostate or breast cancer

AU - Hadji, Peyman

AU - Ziller, May

AU - Maurer, Tobias

AU - Autenrieth, Michael

AU - Muth, Mathias

AU - Ruebel, Amelie

AU - May, Christoph

AU - Birkholz, Katrin

AU - Diebel, Erhardt

AU - Gleissner, Jochen

AU - Rothe, Peter

AU - Gschwend, Juergen E

PY - 2012/12

Y1 - 2012/12

N2 - PURPOSE: The ZOTECT study assesses the effect of zoledronic acid (ZOL) on bone-marker levels and potential correlations with disease outcomes in bisphosphonate-naive patients.METHODS: This prospective, single-arm, open-label study in bisphosphonate-naive (≥6 months) patients with bone metastases from prostate cancer (PC; n=301) or breast cancer (BC; n=99) enrolled at 98 German sites (May 2006 to July 2008) investigated the effect of ZOL (4 mg intravenously every 4 weeks×4 months, with a final follow-up at 12 months) on bone-marker levels. Secondary assessments: skeletal-related event (SRE) rate, pain, quality of life (QoL), and prostate-specific antigen levels. Endpoints were assessed using summary statistics by visit/tumor type and Kaplan-Meier analyses.RESULTS: ZOL treatment significantly decreased bone-marker levels (amino-terminal propeptide of type I collagen [P1NP], C-terminal cross-linking telopeptide of type I collagen [CTX]; P<0.0001), and this decrease was maintained through the final 1-year follow-up visit. Baseline P1NP and CTX levels correlated with extent of bone disease (P<0.0001, each) and on-treatment decreases in marker levels. Skeletal disease burden and bone-marker levels were similar between PC and BC patients, and ZOL did not significantly influence osteoprotegerin/receptor activator of nuclear factor-κB ligand levels. Only 13 SREs occurred in 11 patients, supporting the known ZOL-mediated reduction in SREs. On-treatment bone-marker level changes did not correlate with SRE rate, pain scores, or QoL. Generally, ZOL was well tolerated and adverse events were consistent with its known safety profile.CONCLUSIONS: This study confirms that ZOL therapy significantly reduces bone turnover (measured as P1NP and CTX levels) in patients with bone metastases from PC or BC.

AB - PURPOSE: The ZOTECT study assesses the effect of zoledronic acid (ZOL) on bone-marker levels and potential correlations with disease outcomes in bisphosphonate-naive patients.METHODS: This prospective, single-arm, open-label study in bisphosphonate-naive (≥6 months) patients with bone metastases from prostate cancer (PC; n=301) or breast cancer (BC; n=99) enrolled at 98 German sites (May 2006 to July 2008) investigated the effect of ZOL (4 mg intravenously every 4 weeks×4 months, with a final follow-up at 12 months) on bone-marker levels. Secondary assessments: skeletal-related event (SRE) rate, pain, quality of life (QoL), and prostate-specific antigen levels. Endpoints were assessed using summary statistics by visit/tumor type and Kaplan-Meier analyses.RESULTS: ZOL treatment significantly decreased bone-marker levels (amino-terminal propeptide of type I collagen [P1NP], C-terminal cross-linking telopeptide of type I collagen [CTX]; P<0.0001), and this decrease was maintained through the final 1-year follow-up visit. Baseline P1NP and CTX levels correlated with extent of bone disease (P<0.0001, each) and on-treatment decreases in marker levels. Skeletal disease burden and bone-marker levels were similar between PC and BC patients, and ZOL did not significantly influence osteoprotegerin/receptor activator of nuclear factor-κB ligand levels. Only 13 SREs occurred in 11 patients, supporting the known ZOL-mediated reduction in SREs. On-treatment bone-marker level changes did not correlate with SRE rate, pain scores, or QoL. Generally, ZOL was well tolerated and adverse events were consistent with its known safety profile.CONCLUSIONS: This study confirms that ZOL therapy significantly reduces bone turnover (measured as P1NP and CTX levels) in patients with bone metastases from PC or BC.

KW - Journal Article

U2 - 10.1016/j.jbo.2012.07.002

DO - 10.1016/j.jbo.2012.07.002

M3 - SCORING: Journal article

C2 - 26909262

VL - 1

SP - 88

EP - 94

JO - J BONE ONCOL

JF - J BONE ONCOL

SN - 2212-1374

IS - 3

ER -